Risk of CMV after r-ATG or IL2 Antagonist Induction and the Impact of CMV-Directed Prophylaxis in Low Risk Renal Transplant Recipients
Teena Sam, PharmD, BCPS1, Elise Carlson, PharmD2, Ian C. Doyle, PharmD, BCPS3, Steven Gabardi, PharmD, BCPS4, Karen L. Hardinger, PharmD, BCPS5, John Knorr, PharmD, BCPS6, Lisa M. McDevitt, Pharm.D., BCPS7, Kimi Ueda, PharmD, BCPS8 and Eric Tichy, Pharm.D., BCPS1
1Yale-New Haven Hospital, New Haven, CT
2Sanford Health, Fargo, ND
3Pacific University Oregon School of Pharmacy, Hillsboro, OR
4Department of Pharmacy & Renal Divison, Brigham & Women's Hospital; Department of Medicine, Harvard Medical School, Boston, MA
5UMKC School of Pharmacy, Kansas City, MO
6Albert Einstein Medical Center, Philadelphia, PA
7Tufts Medical Center, Boston, MA
8California Pacific Medical Center, San Francisco, CA
![[ Visit Client Website ]](images/banner.gif)